Hepatitis B virus polymerase blocks pattern recognition receptor signaling via interaction with DDX3: implications for immune evasion.

PLoS Pathogens
Haifeng Wang, Wang-Shick Ryu

Abstract

Viral infection leads to induction of pattern-recognition receptor signaling, which leads to interferon regulatory factor (IRF) activation and ultimately interferon (IFN) production. To establish infection, many viruses have strategies to evade the innate immunity. For the hepatitis B virus (HBV), which causes chronic infection in the liver, the evasion strategy remains uncertain. We now show that HBV polymerase (Pol) blocks IRF signaling, indicating that HBV Pol is the viral molecule that effectively counteracts host innate immune response. In particular, HBV Pol inhibits TANK-binding kinase 1 (TBK1)/IkappaB kinase-epsilon (IKKepsilon), the effector kinases of IRF signaling. Intriguingly, HBV Pol inhibits TBK1/IKKepsilon activity by disrupting the interaction between IKKepsilon and DDX3 DEAD box RNA helicase, which was recently shown to augment TBK1/IKKepsilon activity. This unexpected role of HBV Pol may explain how HBV evades innate immune response in the early phase of the infection. A therapeutic implication of this work is that a strategy to interfere with the HBV Pol-DDX3 interaction might lead to the resolution of life-long persistent infection.

References

Apr 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·G R FosterG R Stark
Feb 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·M A SellsG Acs
Mar 3, 2004·Nature Reviews. Molecular Cell Biology·Sanda Rocak, Patrick Linder
Mar 25, 2004·BioTechniques·Jehan LeeWang-Shick Ryu
Apr 22, 2004·Proceedings of the National Academy of Sciences of the United States of America·Stefan WielandFrancis V Chisari
Oct 16, 2004·The Journal of General Virology·Feng Cao, John E Tavis
Oct 28, 2004·Cell·Venkat S R K YedavalliKuan-Teh Jeang
Mar 16, 2005·The Journal of Experimental Medicine·Julianne StackAndrew G Bowie
May 14, 2005·Journal of Virology·Masanori IsogawaFrancis V Chisari
Jul 15, 2005·Journal of Virology·Stefan F Wieland, Francis V Chisari
Feb 25, 2006·Cell·Shizuo AkiraOsamu Takeuchi
May 24, 2006·Antiviral Research·Fabien Zoulim
Aug 26, 2006·Nature Reviews. Immunology·Kenya Honda, Tadatsugu Taniguchi
Sep 15, 2007·Journal of Virology·Yasuo AriumiNobuyuki Kato
Sep 26, 2007·Immunity·Andreas Pichlmair, Caetano Reis e Sousa
Oct 12, 2007·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jun WuJoerg F Schlaak
Feb 12, 2008·Oncogene·M BotlaguntaV Raman
Mar 15, 2008·Virus Research·Michael Nassal
Jul 2, 2008·The Journal of Experimental Medicine·Takeshi Saito, Michael Gale
Aug 5, 2008·Journal of Viral Hepatitis·S PreissP Revill
Nov 8, 2008·Nature Reviews. Immunology·Andrew G Bowie, Leonie Unterholzner
Jan 14, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jun WuJoerg F Schlaak
Oct 31, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Julie LuciforaFabien Zoulim

❮ Previous
Next ❯

Citations

Feb 11, 2014·Virology Journal·Aurelia Busca, Ashok Kumar
Jun 3, 2014·Journal of Translational Medicine·Emily FunkRohit Talwani
Oct 14, 2014·Future Virology·Rama Kapoor, Shyam Kottilil
Aug 11, 2011·PLoS Pathogens·Yongjun TianJing-hsiung James Ou
Mar 13, 2013·Molecular and Cellular Biology·Lili GuMartina Schröder
Apr 12, 2011·Expert Opinion on Therapeutic Targets·Chen WangBo Wei
May 23, 2012·Expert Opinion on Drug Discovery·Xiaoyong ZhangMengji Lu
Jul 22, 2014·Critical Reviews in Biochemistry and Molecular Biology·Deepak Sharma, Eckhard Jankowsky
Oct 11, 2015·The FEBS Journal·Ming-Chih LaiWoan-Yuh Tarn
Feb 11, 2012·Trends in Immunology·Ben X Wang, Eleanor N Fish
Feb 16, 2016·Expert Opinion on Investigational Drugs·Masaud ShahSangdun Choi
Jun 7, 2015·Biochemical and Biophysical Research Communications·Yun HongShusen Zheng
Apr 23, 2013·Wiley Interdisciplinary Reviews. RNA·Ricardo Soto-Rifo, Théophile Ohlmann
Sep 22, 2012·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jieliang ChenZhenghong Yuan
Mar 3, 2012·Liver International : Official Journal of the International Association for the Study of the Liver·Wenwei YinZhigang Tian
Jul 16, 2015·Reviews in Medical Virology·Fernando Valiente-EcheverríaRicardo Soto-Rifo
Dec 23, 2014·Liver International : Official Journal of the International Association for the Study of the Liver·Carlo Ferrari
Dec 2, 2014·Biochemical and Biophysical Research Communications·Guanghao LiJianfeng Dai
Mar 25, 2011·Biochemical Society Transactions·Martina Schröder
Apr 10, 2013·Biochimica Et Biophysica Acta·Anthony Fullam, Martina Schröder
Jan 2, 2014·Biochemical and Biophysical Research Communications·Quangang ChenLiurong Fang
Sep 28, 2012·Clinical Science·Daniel GrimmRobert Thimme
Mar 12, 2015·Virology·Christoph Seeger, William S Mason
Apr 22, 2015·Future Virology·Daniel N Clark, Jianming Hu
Aug 8, 2014·Frontiers in Immunology·Nelson C Di Paolo
May 20, 2016·Hepatology International·Li-Min ChenYong-Fang Jiang
Jul 5, 2016·Nature Reviews. Immunology·Eui-Cheol ShinSu-Hyung Park

❮ Previous
Next ❯

Methods Mentioned

BETA
transfection
nuclear translocation
confocal microscopy
fluorescence microscopy
co-immunoprecipitation
transgenic
PCR
electrophoresis
Immunoprecipitation
scraping

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Adrenocortical Carcinoma

Hepatocellular carcinoma is the most common type of primary liver cancer and frequently occurs in individuals with chronic liver diseases like cirrhosis. Here is the latest research.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.